Transparency builds trust faster than broad feature claims.
The LifeIndex model uses multiple inputs, but a smaller set of biomarkers currently carries the highest weights because they are both clinically meaningful and consistently available in real-world workflows.
Current top-weighted biomarkers
- ApoB: Strong marker for atherogenic particle burden and long-term cardiovascular risk.
- LDL-C: Useful secondary lipid context when ApoB and broader panel information are available.
- HbA1c: Captures medium-horizon glycemic exposure and metabolic strain.
- Fasting glucose: Adds near-term glycemic signal and intervention responsiveness.
- Systolic blood pressure: High practical value for vascular risk trend interpretation.
- Diastolic blood pressure: Complements systolic pressure for hemodynamic context.
- Resting heart rate trend: Reflects recovery load and cardiorespiratory stress over time.
- hs-CRP: Inflammation context that often explains otherwise inconsistent profile movement.
Why these eight receive heavier weight now
Each selected biomarker performs well on three criteria:
- Interpretability: clinicians can explain movement quickly.
- Repeatability: values are routinely obtainable across retest cycles.
- Actionability: score movement can be tied to concrete protocol changes.
Inputs outside this core set still matter. They are included where available, but are weighted more conservatively when consistency or coverage is lower.
How this should be used
Treat heavy-weighted biomarkers as anchors, not absolutes.
A single marker should never replace domain interpretation, and a single domain should never replace longitudinal context. The score is strongest when trends are reviewed together: lipid direction, metabolic direction, recovery direction, and activity consistency.
What changes next
Weighting decisions are revisited as cohort breadth increases. New candidates must prove reliability and explanatory value before entering high-weight tiers.
Methodology maturity means adding signals carefully, not quickly.